{"product_id":"modd-vrio-analysis","title":"Modular Medical, Inc. (MODD): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Modular Medical, Inc. (MODD) truly built to last? This VRIO analysis distills their entire competitive strategy into four critical questions: Value, Rarity, Inimitability, and Organization. Dive in now to see precisely where their sustainable advantage lies - or where it might be vulnerable.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eModular Medical, Inc. (MODD) - VRIO Analysis: 1. FDA-Cleared MODD1 Insulin Pump Technology\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core asset that Modular Medical, Inc. (MODD) is betting its future on: the FDA-cleared MODD1 Insulin Pump. The immediate takeaway is that this clearance, secured in \u003cstrong\u003eSeptember 2024\u003c\/strong\u003e, allows the company to finally move from pre-revenue status - where they posted a net loss of \u003cstrong\u003e$18.8 million\u003c\/strong\u003e for the fiscal year ended March 31, 2025 - to actual revenue generation starting with initial shipments planned by the quarter ending \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Market Entry and Affordability Proposition\u003c\/h3\u003e\n\u003cp\u003eThe value here is direct market access and a clear value proposition aimed at the underserved. The MODD1 is designed to be simpler and more affordable than existing technology, targeting what the company calls the \u003cstrong\u003e$3 billion\u003c\/strong\u003e \"almost-pumper\" market, which represents about \u003cstrong\u003e70%\u003c\/strong\u003e of insulin-dependent adults still relying on multiple daily injections. The two-part design itself is a value driver: a reusable controller lasts \u003cstrong\u003e90 days\u003c\/strong\u003e, while the disposable cartridge, which includes the battery and infusion set, is replaced every \u003cstrong\u003e3 days\u003c\/strong\u003e. This structure aims to lower the total cost of ownership and reduce the intimidation factor for new pump users.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Design Differentiation in a Crowded Field\u003c\/h3\u003e\n\u003cp\u003eRarity is moderate because the patch pump category isn't empty; Insulet’s Omnipod is a major player. However, the MODD1’s specific combination of simplicity, affordability, and its modular nature - a reusable core component - is less common. While similar in volume to Omnipod, it’s described as \"squatter and wider\". The key differentiator isn't just the form factor, but the explicit design choice to avoid the complexity of current automated systems for its initial launch, though it is built to integrate with CGMs later.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Regulatory Hurdles and Design Complexity\u003c\/h3\u003e\n\u003cp\u003eImitability is difficult, but not impossible. Competitors face significant barriers due to the extensive Research and Development required to create a novel, two-part device, plus the substantial cost and time associated with navigating the U.S. Food and Drug Administration regulatory pathway. While a competitor could eventually design around the specific features, replicating the entire system - including the established manufacturing line validation - is a multi-year, multi-million dollar undertaking. Still, the lack of current closed-loop automation means a competitor focused on advanced algorithms could potentially leapfrog the initial MODD1 offering.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Scaling to Meet Launch Targets\u003c\/h3\u003e\n\u003cp\u003eOrganization is currently being tested by the transition from clearance to commercialization. The company has substantially established its commercial manufacturing infrastructure, and leadership has been bolstered by hiring David Bosshard in October 2025, who has experience scaling similar systems like Omnipod internationally. The success hinges on executing the planned initial shipments by the end of Q3 2025 and effectively managing the \u003cstrong\u003e$19.0 million\u003c\/strong\u003e in operating expenses reported in the last fiscal year. If onboarding and distribution scale smoothly, the organization is adequate; if not, churn risk rises fast.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the current competitive standing:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eKey Data Point (2025 Context)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eTargets \u003cstrong\u003e$3 Billion\u003c\/strong\u003e underserved market segment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eUnique two-part, simple design vs. established patch pumps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003ctd\u003eRequires significant R\u0026amp;D and successful \u003cstrong\u003eFDA Clearance\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eManufacturing ready for Q3 2025 shipments; cash on hand \u003cstrong\u003e$13.1 million\u003c\/strong\u003e as of 3\/31\/2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe competitive advantage is currently \u003cstrong\u003eTemporary\u003c\/strong\u003e. The immediate value is the ability to capture market share from MDI users who want simplicity now, before competitors with more advanced, algorithm-driven systems fully saturate the space. The next test is speed to market and adoption rate.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus on rapid physician adoption post-launch.\u003c\/li\u003e\n\u003cli\u003eSecure favorable insurance\/reimbursement codes quickly.\u003c\/li\u003e\n\u003cli\u003eAccelerate R\u0026amp;D for the Pivot's planned \u003cstrong\u003eQ1 2026\u003c\/strong\u003e launch.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eModular Medical, Inc. (MODD) - VRIO Analysis: 2. Proprietary Patent Portfolio (Eight Families)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Creates a legal barrier to entry, protecting core pumping mechanism features, like the one patented in late 2024.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe patent portfolio is positioned as a strategic asset, with CEO Jeb Besser noting the 'eight families of patents around our pump are an important part of our strategic value and market positioning.' The company announced the issuance of U.S. Patent 11,817,197 B2 on January 24, 2024, protecting streamlined pairing of the pump to a mobile device using Near-Field Communication (NFC) technology. Furthermore, U.S. Divisional Patent Application No. 17\/968,599 was issued in September 2024, covering fundamental features of the pumping mechanism in the FDA-cleared MODD1 product.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Moderate; many medical device firms have patents, but the breadth across eight families is a differentiator.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe portfolio includes 21 total global patents, with 16 active patents, stemming from what the company refers to as eight families. The company raised approximately \\$12 million in March 2025 and \\$8 million at the end of 2024, which supports ongoing R\u0026amp;D and IP maintenance, though the company incurred a net loss of approximately \\$10.3 million for the nine months ended December 31, 2022.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eCount\/Value\u003c\/th\u003e\n\u003cth\u003eDate\/Period Reference\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Global Patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e21\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent (as per one source)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGranted Patents (Global)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent (as per one source)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive Patents (Global)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e16\u003c\/strong\u003e (or \u0026gt;\u003cstrong\u003e76%\u003c\/strong\u003e of total)\u003c\/td\u003e\n\u003ctd\u003eCurrent (as per one source)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent Families Referenced by CEO\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eEight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnique Patent Families (Reported)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent (as per one source)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e32,536,700\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJune 17, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Difficult; patent protection is legally hard to copy without infringement risk.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLegal protection via granted U.S. Patents, such as 11,817,197 B2 and the Divisional Patent Application No. 17\/968,599, creates a direct legal barrier. The company's ability to maintain and enforce this portfolio is tied to its financial health, which showed an accumulated deficit of approximately \\$44.9 million as of December 31, 2022, and a cash balance of approximately \\$7.7 million at that time. The company raised approximately \\$12 million in March 2025, intended in part for supply chain optimization and margin improvement on its MODD1 product.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eU.S. Patent 11,817,197 B2 issued for pump-to-mobile device pairing technology.\u003c\/li\u003e\n\u003cli\u003eU.S. Divisional Patent Application No. 17\/968,599 issued for core pumping mechanism features.\u003c\/li\u003e\n\u003cli\u003eThe company anticipates further patent issuances in the future.\u003c\/li\u003e\n\u003cli\u003eThe MODD1 product has a reservoir size of 300 units\/3mL.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Moderate; the company emphasizes its IP as strategic value, but enforcement requires capital.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company explicitly frames its intellectual property as a key component of its strategic value. However, the need for capital to support operations and potential enforcement is evident, as evidenced by the \\$12 million private placement in March 2025 and the \\$8 million raised at the end of 2024. The net loss for the year ended March 31, 2022, was approximately \\$18.6 million.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained; strong, broad IP can provide a long-term moat if maintained.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe protection afforded by the eight families of patents, covering core pumping technology and data transfer, is intended to create a 'significant new barrier to entry.' The company's market capitalization was \\$26.7M as of November 12, 2025, on 63.6M shares outstanding. The success of this advantage is contingent on leveraging the IP into commercial success, with FDA clearance for MODD1 received in September (prior to the September 2024 patent announcement).\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eModular Medical, Inc. (MODD) - VRIO Analysis: 3. Pivot Next-Generation Insulin Pump Pipeline\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Represents future revenue potential by addressing the next level of usability and potentially capturing a larger market share.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eValue Metrics\u003c\/h\u003e\u003c\/h\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Market Size\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$3 billion\u003c\/strong\u003e USD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Segment\u003c\/td\u003e\n\u003ctd\u003eAdult 'almost-pumpers'\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePivot Pump Capacity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3 milliliter\u003c\/strong\u003e removable patch pump\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Commercial Launch\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ1 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare; having a next-gen product already in validation (controller line validated Nov 2025) is uncommon for a pre-revenue firm.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity Milestones\u003c\/h\u003e\u003c\/h\u003e\n\u003cul\u003e\n\u003cli\u003ePivot Controller Line Validation Date: \u003cstrong\u003eNovember 3, 2025\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eFDA 510(k) Submission Date: \u003cstrong\u003eNovember 14, 2025\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eIRB Approval for Insulin Delivery Study: \u003cstrong\u003eNovember 17, 2025\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; requires similar engineering talent and regulatory pathway execution.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability Context\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe Pivot system is described as the first two-part tubeless patch pump of its kind.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the appointment of David Bosshard in October 2025 signals strong organization for international Pivot rollout.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganizational Data\u003c\/h\u003e\u003c\/h\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eExecutive\u003c\/th\u003e\n\u003cth\u003eRole Appointed\u003c\/th\u003e\n\u003cth\u003eAppointment Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDavid Bosshard\u003c\/td\u003e\n\u003ctd\u003eHead of International Operations\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOctober 6, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eDavid Bosshard International Track Record:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLed successful launch of Insulet's Omnipod patch pump in Europe at Ypsomed AG from \u003cstrong\u003e2010 to 2017\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGrew Omnipod user base to nearly \u003cstrong\u003e70,000\u003c\/strong\u003e users in Europe.\u003c\/li\u003e\n\u003cli\u003eOversaw business operations for \u003cstrong\u003e13\u003c\/strong\u003e country affiliates.\u003c\/li\u003e\n\u003cli\u003eSpearheaded the \u003cstrong\u003e2017\u003c\/strong\u003e launch of YpsoPump, distributed in over \u003cstrong\u003e20\u003c\/strong\u003e countries across Europe, Australia, and Canada.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; a strong, near-term pipeline reduces obsolescence risk for the MODD1.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eContextual Financial Data (As of November 2025)\u003c\/h\u003e\u003c\/h\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock Price\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.48\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of 12-Nov-2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Cap\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$26.7M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of 12-Nov-2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e63.6M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of 12-Nov-2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrailing 12-Month Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003enull\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of 30-Sep-2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBITDA (TTM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e($22,813) Thousand USD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of 30-Sep-2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eModular Medical, Inc. (MODD) - VRIO Analysis: 4. Experienced Founding\/Executive Team\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eReduces execution risk, drawing on the founder's history with Tandem Diabetes and the t:slim pump design. Paul DiPerna, Chairman \u0026amp; CTO, is the Founder of Tandem Diabetes (TNDM:NAS). CEO James (Jeb) Besser is the designer and lead developer of the t:slim pump.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRare; direct, successful prior experience in the specific insulin pump market is scarce. Paul DiPerna has 30 years of experience in the medical device industry and has led over 10 projects to FDA approval.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDifficult; deep, tacit knowledge and industry relationships are hard to replicate quickly. New Head of International Operations, David Bosshard, leveraged success in launching Insulet's Omnipod, growing the user base to nearly 70,000 while overseeing business operations for 13 country affiliates.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; leadership is actively making strategic hires, like the Head of International Operations. The appointment of David Bosshard as Head of International Operations was announced on October 6, 2025. The company has 54 Employees.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained; experienced leadership is a foundational, hard-to-copy asset. The management team possesses deep domain expertise, exemplified by Paul DiPerna's 30-year veteran status in the medical device industry, targeting the $3 billion adult 'almost-pumpers' diabetes market.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eExecutive Role\u003c\/td\u003e\n\u003ctd\u003eExecutive Name\u003c\/td\u003e\n\u003ctd\u003eRelevant Experience\/Metric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChairman \u0026amp; CTO \/ Founder\u003c\/td\u003e\n\u003ctd\u003ePaul DiPerna\u003c\/td\u003e\n\u003ctd\u003e30 years of medical device industry experience; Founder of Tandem Diabetes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChief Executive Officer\u003c\/td\u003e\n\u003ctd\u003eJames (Jeb) Besser\u003c\/td\u003e\n\u003ctd\u003eDesigner and lead developer of t:slim pump; CEO tenure since Feb 2022 (3.83 years)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHead of International Operations\u003c\/td\u003e\n\u003ctd\u003eDavid Bosshard\u003c\/td\u003e\n\u003ctd\u003eGrew Omnipod user base to nearly 70,000 in Europe across 13 country affiliates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe leadership team's history includes key milestones such as the Tandem Diabetes Care – 510k approval on their T-Slim –2012.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCEO Jeb Besser directly owns 0.66% of the company's shares, valued at $177.71K.\u003c\/li\u003e\n\u003cli\u003eThe company is advancing its Pivot insulin delivery system through U.S. and CE Mark regulatory processes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eModular Medical, Inc. (MODD) - VRIO Analysis: 5. Targeted Market Strategy ('Almost-Pumpers')\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFocuses on the estimated \u003cstrong\u003e$3 billion\u003c\/strong\u003e US market segment of 'almost-pumpers,' individuals avoiding current pumps due to cost or complexity. The Pivot product offers a clear value proposition with a \u003cstrong\u003e3 mL\u003c\/strong\u003e reservoir, larger than the \u003cstrong\u003e2 mL or less\u003c\/strong\u003e typical of other patch pumps.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; the specific focus on 'diabetes care for the rest of us' carves out a niche. The Pivot is positioned as the first tubeless, removable \u003cstrong\u003e3 milliliter\u003c\/strong\u003e patch pump. The broader US market includes \u003cstrong\u003e27 million\u003c\/strong\u003e people with diabetes, with \u003cstrong\u003e3.6 million\u003c\/strong\u003e requiring daily insulin.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; competitors can pivot messaging, but winning over this skeptical group requires time. The company's design philosophy aims to eliminate the tradeoff between complexity and efficacy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; the entire product design philosophy for MODD1 and Pivot aligns with this target. The company has completed production of over \u003cstrong\u003e6,000\u003c\/strong\u003e MODD1 cartridges and validated the Pivot controller line for high-volume production.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary; a clear focus is beneficial, but if major players shift focus, this advantage erodes. The company anticipates a Pivot launch in Q1 \u003cstrong\u003e2026\u003c\/strong\u003e, following an expected FDA submission in October \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eQuantitative Data Summary:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Product\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTargeted US Market Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e'Almost-Pumpers' Segment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePivot Reservoir Capacity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3 mL\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFirst tubeless, removable patch pump of this size\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical Competitor Reservoir\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2 mL or less\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOther patch pumps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal US Diabetes Population\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e27 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOverall US Market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Daily Insulin Users\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eT1D and T2D combined\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Annual Savings Per Patient\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10k (40%)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEven after pump cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMODD1 Cartridges Manufactured\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e6,000\u003c\/strong\u003e units\u003c\/td\u003e\n\u003ctd\u003eProduction Milestone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$18.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal Year Ended March 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Balance (as of March 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFinancial Position\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAlignment with Design Philosophy:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe mission is to provide 'diabetes care for the rest of us,' moving beyond 'superusers.'\u003c\/li\u003e\n\u003cli\u003ePivot design eliminates excess complexity, featuring a tubeless, removable design.\u003c\/li\u003e\n\u003cli\u003eThe manufacturing platform is specifically designed for high-volume production.\u003c\/li\u003e\n\u003cli\u003ePivot enables bolus dosing without an external controller.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eModular Medical, Inc. (MODD) - VRIO Analysis: 6. Validated High-Volume Manufacturing Readiness\n\u003c\/h2\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003ch\u003e\n\u003cp\u003eCrucial for meeting anticipated demand post-launch and achieving economies of scale to support lower pricing. The company targets a $3 billion market opportunity with its Pivot product. Industry data suggests insulin pumps can reduce typical expense per patient year from approximately $27,000 to $17,000.\u003c\/p\u003e\n\u003c\/h\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003ch\u003e\n\u003cp\u003eRare; many medical device startups struggle to scale manufacturing post-FDA clearance.\u003c\/p\u003e\n\u003c\/h\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003ch\u003e\n\u003cp\u003eDifficult; requires significant capital investment and successful validation runs. The successful validation of the Pivot controller line occurred in late 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eManufacturing Milestone\u003c\/th\u003e\n\u003cth\u003eDate\/Status\u003c\/th\u003e\n\u003cth\u003eAssociated Product\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMODD1 Cartridge Line Validated for Human-Use Production\u003c\/td\u003e\n\u003ctd\u003eAugust 2025\u003c\/td\u003e\n\u003ctd\u003eMODD1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMODD1 Cartridge Units Manufactured\u003c\/td\u003e\n\u003ctd\u003eOver 6,000 units\u003c\/td\u003e\n\u003ctd\u003eMODD1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePivot Controller Line Validated for Human-Use Production\u003c\/td\u003e\n\u003ctd\u003eNovember 3, 2025\u003c\/td\u003e\n\u003ctd\u003ePivot\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePivot FDA 510(k) Submission\u003c\/td\u003e\n\u003ctd\u003eNovember 14, 2025\u003c\/td\u003e\n\u003ctd\u003ePivot\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/h\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003ch\u003e\n\u003cp\u003eHigh; validation is a concrete organizational achievement demonstrating operational maturity. The company is working with manufacturing partner Phillips Medisize, a Molex company.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePivot is designed as a tubeless, removable 3 milliliter patch pump.\u003c\/li\u003e\n\u003cli\u003eMODD1 system has a reservoir size of 300 units\/3mL.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/h\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003ch\u003e\n\u003cp\u003eSustained; scalable manufacturing readiness is a high barrier for smaller, less capitalized rivals. The validated line supports the targeted Q1 2026 commercial launch for Pivot.\u003c\/p\u003e\n\u003c\/h\u003e\n\n\u003cbr\u003e\u003ch2\u003eModular Medical, Inc. (MODD) - VRIO Analysis: 7. Low Debt Structure (FY 2025 Total Debt: $816K)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Provides financial flexibility and reduces fixed interest obligations, which is vital given the negative EBITDA. The FY 2025 EBITDA was reported as ($17,759K) in thousands of USD.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Rare; many development-stage firms carry significant debt loads; Modular Medical is near debt-free. The Debt-to-Equity ratio was reported as 0.07 or 6.97%.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Easy; the company achieved this by financing through equity offerings, which is an organizational choice, not a unique resource.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Moderate; the finance team has successfully managed to keep debt low, but reliance on equity is a risk.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary; this low-debt position can quickly change if a large debt raise is needed for commercial scale.\u003c\/p\u003e\n\u003cp\u003eKey financial metrics supporting the low debt structure assessment are presented below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY 2025 Value\u003c\/th\u003e\n\u003cth\u003eTrailing Twelve Months (TTM) Value\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt (in Thousands USD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e816\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e611\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIndicates a minimal debt burden relative to assets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBITDA (in Thousands USD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e(17,759)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e(22,813)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNegative operational performance necessitates low fixed costs like interest\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets (in Thousands USD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18,735\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12,974\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTotal Assets for FY 2025 were \u003cstrong\u003e$18.735 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company's financing strategy has relied on equity issuance to maintain this structure:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company completed a public offering in November 2024, raising net proceeds of \u003cstrong\u003e$7.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eA private placement in March 2025 raised approximately \u003cstrong\u003e$12 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Total Liabilities for FY2025 were reported as \u003cstrong\u003e$1.66M\u003c\/strong\u003e, with a year-on-year change of \u003cstrong\u003e-27.02%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eModular Medical, Inc. (MODD) - VRIO Analysis: 8. Total Assets Base (FY 2025: $18.735M)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Provides the necessary capital base to fund ongoing R\u0026amp;D, which was \u003cstrong\u003e$14.7M\u003c\/strong\u003e in FY 2025, and initial commercialization efforts.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate; \u003cstrong\u003e$18.735 million\u003c\/strong\u003e in total assets is typical for a late-stage, pre-revenue device company.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Easy; assets are primarily cash raised from public\/private offerings, which is replicable by issuing more stock.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Moderate; the organization must deploy these assets effectively to avoid a high cash burn rate, evidenced by a FY 2025 Net Loss of \u003cstrong\u003e($18.824M)\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: None; assets are fungible and reflect past fundraising, not unique capability.\u003c\/p\u003e\n\u003cp\u003eKey financial metrics supporting the Total Assets Base assessment for Fiscal Year 2025:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eFY 2025 Amount\u003c\/td\u003e\n\u003ctd\u003eContext\/Note\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$18.735M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported total assets for FY 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development Expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.7M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFY 2025 R\u0026amp;D spend.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents (as of 3\/31\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.1M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported cash balance as of the fiscal year-end.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.52M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFY 2025 Current Assets figure.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e($18.824M)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFY 2025 Net Loss in thousands.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.816M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFY 2025 Total Debt in thousands.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe deployment of capital is critical given the operational status:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal Operating Expenses for FY 2025 reached \u003cstrong\u003e$19.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Equity as of FY 2025 was reported at \u003cstrong\u003e$17.08M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents as of December 31, 2024, were \u003cstrong\u003e$7.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eModular Medical, Inc. (MODD) - VRIO Analysis: 9. Brand Association\/Reputation (Emerging from Founder's History)\n\u003c\/h2\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eCreates initial credibility with investors and potentially prescribers, leveraging the founder's success with Tandem Diabetes.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTransaction\/Event\u003c\/th\u003e\n\u003cth\u003eFounder's Company\u003c\/th\u003e\n\u003cth\u003eAmount\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIPO\u003c\/td\u003e\n\u003ctd\u003eTandem Diabetes Care (TNDM)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$450M\u003c\/strong\u003e (2013)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition Cash (AMF Sigi Pump)\u003c\/td\u003e\n\u003ctd\u003eTandem Diabetes Care (TNDM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$69M USD\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition Milestones (AMF Sigi Pump)\u003c\/td\u003e\n\u003ctd\u003eTandem Diabetes Care (TNDM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$143M USD\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate; founder reputation is a soft asset that carries weight in specialized fields.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eDifficult; personal history and reputation are not easily copied, though the company is still building its own brand.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eModerate; the organization must actively communicate this pedigree to maximize its effect.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCEO Gross Remuneration (Jeb Besser): \u003cstrong\u003e$1\u003c\/strong\u003e per year.\u003c\/li\u003e\n\u003cli\u003eFounder\/President Gross Remuneration (Paul DiPerna): \u003cstrong\u003e$482.79K\u003c\/strong\u003e (2025).\u003c\/li\u003e\n\u003cli\u003eEmployee Count: \u003cstrong\u003e54\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary; this initial halo effect will fade as the MODD1 and Pivot products stand on their own merits.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMODD1 FDA Clearance: September \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMODD1 Initial Shipments Planned: Quarter ending September \u003cstrong\u003e30, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePivot Target Market: \u003cstrong\u003e$3 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePivot Regulatory Clearance Target: By March \u003cstrong\u003e31, 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eFinance\u003c\/h\u003e\n\u003cp\u003eDraft 13-week cash view by Friday.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash (Latest Reported): \u003cstrong\u003e$5.32 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Cash Position: \u003cstrong\u003e$4.71 million\u003c\/strong\u003e or \u003cstrong\u003e$0.07\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003cli\u003eShares Outstanding: \u003cstrong\u003e63.60 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOperating Cash Flow (TTM): \u003cstrong\u003e-$19.19 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFree Cash Flow (TTM): \u003cstrong\u003e-$22.38 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ1 2026 Net Loss: \u003cstrong\u003e$6.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Operating Expenses (Latest Reported): \u003cstrong\u003e$19.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516209619093,"sku":"modd-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/modd-vrio-analysis.png?v=1740196113","url":"https:\/\/dcf-model.com\/pt\/products\/modd-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}